{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"A Phase 3 Open-label Randomized Study Assessing the Efficacy and Safety of\nRLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for\nPIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor\nReceptor 2 Negative (HR+\/HER2-) Locally Advanced or Metastatic Breast Cancer\nFollowing Recurrence or Progression On or After Treatment with a CDK4\/6\nInhibitor","item":"https:\/\/www.regionalcancercare.org\/trials\/a-phase-3-open-label-randomized-study-assessing-the-efficacy-and-safety-ofrly-2608-fulvestrant-versus-capivasertib-fulvestrant-as-treatment-forpik3ca-mutant-hormone-receptor-positive-human-epid\/#breadcrumbitem"}]}